Barclays’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $412M | Sell |
14,689,187
-3,444,802
| -19% | -$91.7M | 0.1% | 150 |
|
|
2025
Q4 | $452M | Sell |
18,133,989
-411,569
| -2% | -$10.4M | 0.11% | 137 |
|
|
2025
Q3 | $473M | Buy |
18,545,558
+2,970,470
| +19% | +$73.3M | 0.1% | 131 |
|
|
2025
Q2 | $378M | Buy |
15,575,088
+656,946
| +4% | +$15.3M | 0.09% | 152 |
|
|
2025
Q1 | $378M | Sell |
14,918,142
-1,962,267
| -12% | -$51.3M | 0.11% | 146 |
|
|
2024
Q4 | $448M | Sell |
16,880,409
-10,203,305
| -38% | -$277M | 0.13% | 110 |
|
|
2024
Q3 | $784M | Buy |
27,083,714
+11,840,905
| +78% | +$345M | 0.21% | 60 |
|
|
2024
Q2 | $426M | Sell |
15,242,809
-6,322,497
| -29% | -$174M | 0.13% | 117 |
|
|
2024
Q1 | $598M | Buy |
21,565,306
+9,939,752
| +85% | +$276M | 0.21% | 84 |
|
|
2023
Q4 | $335M | Sell |
11,625,554
-4,503,233
| -28% | -$136M | 0.12% | 134 |
|
|
2023
Q3 | $535M | Buy |
16,128,787
+3,102,892
| +24% | +$110M | 0.33% | 55 |
|
|
2023
Q2 | $478M | Buy |
13,025,895
+6,466,670
| +99% | +$252M | 0.3% | 65 |
|
|
2023
Q1 | $268M | Sell |
6,559,225
-5,941,259
| -48% | -$257M | 0.12% | 102 |
|
|
2022
Q4 | $641M | Buy |
12,500,484
+3,310,499
| +36% | +$159M | 0.29% | 44 |
|
|
2022
Q3 | $402M | Buy |
9,189,985
+1,993,130
| +28% | +$96.9M | 0.44% | 35 |
|
|
2022
Q2 | $377M | Sell |
7,196,855
-4,125,023
| -36% | -$210M | 0.23% | 59 |
|
|
2022
Q1 | $586M | Sell |
11,321,878
-3,779,832
| -25% | -$196M | 0.46% | 37 |
|
|
2021
Q4 | $892M | Buy |
15,101,710
+574,305
| +4% | +$28.5M | 0.33% | 52 |
|
|
2021
Q3 | $625M | Buy |
14,527,405
+4,470,323
| +44% | +$198M | 0.28% | 57 |
|
|
2021
Q2 | $394M | Buy |
10,057,082
+1,459,377
| +17% | +$56.8M | 0.19% | 77 |
|
|
2021
Q1 | $311M | Sell |
8,597,705
-463,591
| -5% | -$16.5M | 0.17% | 89 |
|
|
2020
Q4 | $334M | Sell |
9,061,296
-5,977,248
| -40% | -$219M | 0.18% | 87 |
|
|
2020
Q3 | $524M | Buy |
15,038,544
+6,148,179
| +69% | +$216M | 0.31% | 49 |
|
|
2020
Q2 | $276M | Buy |
8,890,365
+36,311
| +0.4% | +$1.23M | 0.21% | 69 |
|
|
2020
Q1 | $274M | Sell |
8,854,054
-4,708,612
| -35% | -$160M | 0.22% | 65 |
|
|
2019
Q4 | $504M | Sell |
13,562,666
-87,896
| -0.6% | -$3.13M | 0.28% | 64 |
|
|
2019
Q3 | $465M | Sell |
13,650,562
-897,261
| -6% | -$32.6M | 0.29% | 47 |
|
|
2019
Q2 | $598M | Sell |
14,547,823
-917,945
| -6% | -$36.5M | 0.37% | 42 |
|
|
2019
Q1 | $623M | Buy |
15,465,768
+1,369,237
| +10% | +$54.8M | 0.43% | 27 |
|
|
2018
Q4 | $584M | Sell |
14,096,531
-871,702
| -6% | -$36.2M | 0.45% | 28 |
|
|
2018
Q3 | $626M | Sell |
14,968,233
-215,414
| -1% | -$8.29M | 0.43% | 26 |
|
|
2018
Q2 | $523M | Buy |
15,183,647
+1,094,571
| +8% | +$37.4M | 0.45% | 23 |
|
|
2018
Q1 | $474M | Buy |
14,089,076
+2,466,478
| +21% | +$84.8M | 0.36% | 38 |
|
|
2017
Q4 | $399M | Buy |
11,622,598
+1,860,455
| +19% | +$63.4M | 0.33% | 54 |
|
|
2017
Q3 | $331M | Buy |
9,762,143
+1,149,383
| +13% | +$36.9M | 0.34% | 36 |
|
|
2017
Q2 | $274M | Buy |
8,612,760
+624,071
| +8% | +$19.7M | 0.29% | 45 |
|
|
2017
Q1 | $259M | Buy |
7,988,689
+439,498
| +6% | +$13.9M | 0.28% | 44 |
|
|
2016
Q4 | $233M | Sell |
7,549,191
-728,285
| -9% | -$22.2M | 0.25% | 54 |
|
|
2016
Q3 | $266M | Sell |
8,277,476
-19,463
| -0.2% | -$651K | 0.3% | 43 |
|
|
2016
Q2 | $277M | Sell |
8,296,939
-395,541
| -5% | -$12.6M | 0.36% | 32 |
|
|
2016
Q1 | $239M | Sell |
8,692,480
-5,847,970
| -40% | -$167M | 0.36% | 35 |
|
|
2015
Q4 | $441M | Buy |
14,540,450
+65,057
| +0.4% | +$2.05M | 0.54% | 20 |
|
|
2015
Q3 | $426M | Buy |
14,475,393
+1,235,368
| +9% | +$39.6M | 0.51% | 19 |
|
|
2015
Q2 | $415M | Buy |
13,240,025
+1,389,403
| +12% | +$45.3M | 0.47% | 18 |
|
|
2015
Q1 | $382M | Buy |
11,850,622
+1,276,323
| +12% | +$40.6M | 0.44% | 20 |
|
|
2014
Q4 | $311M | Sell |
10,574,299
-1,331,224
| -11% | -$38.2M | 0.3% | 45 |
|
|
2014
Q3 | $328M | Buy |
11,905,523
+294,849
| +3% | +$8.28M | 0.32% | 38 |
|
|
2014
Q2 | $319M | Buy |
11,610,674
+480,940
| +4% | +$13.7M | 0.34% | 39 |
|
|
2014
Q1 | $338M | Sell |
11,129,734
-1,578,399
| -12% | -$47.1M | 0.38% | 34 |
|
|
2013
Q4 | $362M | Buy |
12,708,133
+1,507,461
| +13% | +$43.9M | 0.37% | 29 |
|
|
2013
Q3 | $298M | Sell |
11,200,672
-17,234,180
| -61% | -$469M | 0.36% | 29 |
|
|
2013
Q2 | $756M | Buy |
+28,434,852
| New | +$786M | 0.94% | 8 |
|
Other funds holding PFE
VCM
VPM
Barclays's PFE Position: Q1 2026 in Review
Barclays reduced its Pfizer (PFE) stake by 19% in Q1 2026, selling an estimated $91.7M and leaving 14,689,187 shares worth $412M. The position accounts for 0.1% of the portfolio, ranked #150.
Barclays first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $892M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Barclays held 14,689,187 shares of Pfizer worth $412M as of Q1 2026.
- Barclays sold 3,444,802 Pfizer shares in Q1 2026, an estimated $91.7M.
- Pfizer made up 0.1% of Barclays's portfolio in Q1 2026, its #150 holding.
- Barclays first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Barclays's Pfizer position peaked at $892M in Q4 2021.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.